BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 31417187)

  • 1. Inhibition of DOT1L and PRMT5 promote synergistic anti-tumor activity in a human MLL leukemia model induced by CRISPR/Cas9.
    Secker KA; Keppeler H; Duerr-Stoerzer S; Schmid H; Schneidawind D; Hentrich T; Schulze-Hentrich JM; Mankel B; Fend F; Schneidawind C
    Oncogene; 2019 Nov; 38(46):7181-7195. PubMed ID: 31417187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML.
    Kaushik S; Liu F; Veazey KJ; Gao G; Das P; Neves LF; Lin K; Zhong Y; Lu Y; Giuliani V; Bedford MT; Nimer SD; Santos MA
    Leukemia; 2018 Feb; 32(2):499-509. PubMed ID: 28663579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
    Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
    Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR Gene Editing of Murine Blood Stem and Progenitor Cells Induces MLL-AF9 Chromosomal Translocation and MLL-AF9 Leukaemogenesis.
    Sarrou E; Richmond L; Carmody RJ; Gibson B; Keeshan K
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32549410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
    Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
    J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.
    Deshpande AJ; Chen L; Fazio M; Sinha AU; Bernt KM; Banka D; Dias S; Chang J; Olhava EJ; Daigle SR; Richon VM; Pollock RM; Armstrong SA
    Blood; 2013 Mar; 121(13):2533-41. PubMed ID: 23361907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
    Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
    Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.
    Daigle SR; Olhava EJ; Therkelsen CA; Basavapathruni A; Jin L; Boriack-Sjodin PA; Allain CJ; Klaus CR; Raimondi A; Scott MP; Waters NJ; Chesworth R; Moyer MP; Copeland RA; Richon VM; Pollock RM
    Blood; 2013 Aug; 122(6):1017-25. PubMed ID: 23801631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias.
    Yi Y; Ge S
    J Hematol Oncol; 2022 Mar; 15(1):35. PubMed ID: 35331314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small-molecule inhibitor of AF9/ENL-DOT1L/AF4/AFF4 interactions suppresses malignant gene expression and tumor growth.
    Wu F; Nie S; Yao Y; Huo T; Li X; Wu X; Zhao J; Lin YL; Zhang Y; Mo Q; Song Y
    Theranostics; 2021; 11(17):8172-8184. PubMed ID: 34373735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MLL leukemia induction by genome editing of human CD34+ hematopoietic cells.
    Buechele C; Breese EH; Schneidawind D; Lin CH; Jeong J; Duque-Afonso J; Wong SH; Smith KS; Negrin RS; Porteus M; Cleary ML
    Blood; 2015 Oct; 126(14):1683-94. PubMed ID: 26311362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MAT2A as Key Regulator and Therapeutic Target in
    Secker KA; Bloechl B; Keppeler H; Duerr-Stoerzer S; Schmid H; Schneidawind D; Jeong J; Hentrich T; Schulze-Hentrich JM; Schneidawind C
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32456310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy.
    Liu W; Deng L; Song Y; Redell M
    PLoS One; 2014; 9(5):e98270. PubMed ID: 24858818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
    Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
    Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
    Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
    J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.
    Rau RE; Rodriguez BA; Luo M; Jeong M; Rosen A; Rogers JH; Campbell CT; Daigle SR; Deng L; Song Y; Sweet S; Chevassut T; Andreeff M; Kornblau SM; Li W; Goodell MA
    Blood; 2016 Aug; 128(7):971-81. PubMed ID: 27335278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective DOT1L, LSD1, and HDAC Class I Inhibitors Reduce HOXA9 Expression in MLL-AF9 Rearranged Leukemia Cells, But Dysregulate the Expression of Many Histone-Modifying Enzymes.
    Lillico R; Lawrence CK; Lakowski TM
    J Proteome Res; 2018 Aug; 17(8):2657-2667. PubMed ID: 29972300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
    Dzama MM; Steiner M; Rausch J; Sasca D; Schönfeld J; Kunz K; Taubert MC; McGeehan GM; Chen CW; Mupo A; Hähnel P; Theobald M; Kindler T; Koche RP; Vassiliou GS; Armstrong SA; Kühn MWM
    Blood; 2020 Nov; 136(21):2442-2456. PubMed ID: 32589720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis.
    Nguyen AT; Taranova O; He J; Zhang Y
    Blood; 2011 Jun; 117(25):6912-22. PubMed ID: 21521783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed lineage leukemia (MLL) fusion proteins.
    Shen C; Jo SY; Liao C; Hess JL; Nikolovska-Coleska Z
    J Biol Chem; 2013 Oct; 288(42):30585-30596. PubMed ID: 23996074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.